AcelRx Pharmaceuticals Inc. (ACRX) announced Friday morning that, following communications with the FDA, the Company is targeting resubmission of the Zalviso NDA in the first quarter of 2015.
AcelRx Pharmaceuticals gapped open sharply lower Friday and dipped in early trade, before settling into a range. Shares finished down by 1.31 at $5.41 on strong volume. The stock dropped below a 2-month range and set a new low for the year.
For comments and feedback contact: editorial@rttnews.com
Business News